Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 25 July 2022, 09:00 HKT/SGT
Share:
    

Source: Novotech Health Holdings Pte Ltd
Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022"

SYDNEY, AU, July 25, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, has been recognised for its innovative approach to workplace flexibility.

Novotech CEO Dr. John Moller said: "Our flexible workplace design, information technology infrastructure, and flexible resourcing of projects are consistently delivering successful outcomes for our team members, clients, and all stakeholders. We are extremely pleased our workplace flexibility efforts are recognised by the Best Workplace Flexibility Program which has selected Novotech as an Excellence Awardee in 2022."

Novotech Chief People Officer Angela Edwardson said that "over the last 12 months, Novotech has re-imagined what flexible working looks like for teams, clients, and the business. This renewed way of working incorporates flexible, remote, and in-office working options and aims to create a dynamic business environment and trusted culture. Team members can determine and apply the most effective way to work, unlocking the maximum value of their talent to benefit all stakeholders."

Some of the new flexible working policies include:
- FlexLocation: Work from home, office or other suitable location.
- FlexTime: Flexible start/finish times
- FlexBreak:Bbreaks during the day for wellbeing or other commitments.
- FlexHours: An adjustment to contracted hours, either permanently or temporarily (ie: full-time to part-time).
- FlexPlace: The option to work at other Novotech offices or cities/countries without a Novotech office temporarily.
- FlexStudy: A combination of Flex options and/or leave to meet study commitments.
- FlexHolidays: The option to select alternate dates in lieu of allocated celebration/public holidays.
- FlexLeave: Leave can be taken by the hour and in combination with other leave types and flexible options.
- FlexTimeout: Extended unpaid leave to pursue and interest, relax or attend to caring responsibilities
- FlexPersonal: A combination of day-to-day and/or planned options.

"Already 17 team members have used or are planning to use FlexPlace in 2022," said Edwardson. "Novotech has a large cohort of expatriate workers, and our new addition of FlexPlace supports them to re-connect with their families and friends or travel while still meeting their working requirements."

Novotech's Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions.

Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.

Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes.

The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.

About Novotech

Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


Topic: Press release summary
Source: Novotech Health Holdings Pte Ltd

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Novotech Health Holdings Pte Ltd
Nov 11, 2022 17:00 HKT/SGT
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
Oct 25, 2022 18:00 HKT/SGT
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
Oct 17, 2022 11:00 HKT/SGT
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval
Oct 12, 2022 09:00 HKT/SGT
Novotech India Recognised as "Best Workplaces for Women 2022" by Global Work Standards Authority
Oct 7, 2022 10:00 HKT/SGT
Novotech Selected as Scrip Awards Finalist for Best Full-Service CRO
Sept 15, 2022 17:00 HKT/SGT
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference
Sept 5, 2022 18:00 HKT/SGT
Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC
Sept 2, 2022 14:00 HKT/SGT
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report
July 18, 2022 16:00 HKT/SGT
Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T"
July 13, 2022 14:30 HKT/SGT
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: